CLINICAL AND LABORATORY STANDARDS INSTITUTE®

3rd Edition

EP07

Interference Testing in Clinical Chemistry

This guideline provides background information, guidance, and experimental procedures for investigating, identifying, and characterizing the effects of interferents on clinical chemistry test results.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes,* is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

EP07, 3rd ed.
April 2018
Replaces EP07-A2

Interference Testing in Clinical Chemistry

Robert J. McEnroe, PhD
Goce Dimeski, PhD, FFSc (RCPA)
A. Paul Durham, MA
James J. Miller, PhD, DABCC, FACB
W. Gregory Miller, PhD
Victoria Petrides, MS
Douglas W. Rheinheimer, MT
Merle B. Smith, MBA, MS, MT(ASCP)
Oswald Sonntag, PhD
Karen L. Warren, MS
Michelle L. Zaharik, PhD

Abstract

Clinical and Laboratory Standards Institute guideline EP07—*Interference Testing in Clinical Chemistry* is intended to promote uniformity in the evaluation of interference characteristics of medical laboratory measurement procedures. EP07 describes procedures to screen potential interferents, quantify interference effects, and confirm interference in patient samples. This guideline also describes procedures for medical laboratories to verify interference claims and investigate discrepant results caused by unsuspected interferents. Detailed examples are given. EP07 also contains background information on interference testing concepts. Tables of recommended test concentrations for potential interferents can be found in the supplement, CLSI document EP37.[1]

Clinical and Laboratory Standards Institute (CLSI). *Interference Testing in Clinical Chemistry*. 3rd ed. CLSI guideline EP07 (ISBN 1-56238-846-0 [Print]; ISBN 1-56238-847-9 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.

Suggested Citation

CLSI. *Interference Testing in Clinical Chemistry.* 3rd ed. CLSI guideline EP07. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

Previous Editions:

August 1986, December 2002, November 2005

Reaffirmed:

October 2022

ISBN 1-56238-846-0 (Print)

ISBN 1-56238-847-9 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 38, Number 7

Committee Membership

Consensus Council

Dennis J. Ernst, MT(ASCP), NCPT(NCCT)
Chairholder
Center for Phlebotomy Education
USA

Mary Lou Gantzer, PhD, FACB
Vice-Chairholder
USA

J. Rex Astles, PhD, FACB, DABCC
Centers for Disease Control and Prevention
USA

Lucia M. Berte, MA, MT(ASCP)SBB, DLM, CQA(ASQ)CMQ/OE
Laboratories Made Better!
USA

Karen W. Dyer, MT(ASCP), DLM
Centers for Medicare & Medicaid Services
USA

Thomas R. Fritsche, MD, PhD, FCAP, FIDSA
Marshfield Clinic
USA

Loralie J. Langman, PhD, DABCC, FACB, F-ABFT
Mayo Clinic
USA

Ross J. Molinaro, PhD, MLS(ASCP)CM, DABCC, FACB
Siemens Healthcare Diagnostics, Inc.
USA

Andrew Quintenz
Bio-Rad Laboratories, Inc.
USA

Robert Rej, PhD
New York State Department of Health Wadsworth Center
USA

Zivana Tezak, PhD
FDA Center for Devices and Radiological Health
USA

Document Development Committee on Interference Testing in Clinical Chemistry

Robert J. McEnroe, PhD
Chairholder
USA

Victoria Petrides, MS
Abbott
USA

Douglas W. Rheinheimer, MT
FDA Center for Devices and Radiological Health
USA

Wadid Sadek, PharmD, MS, PhD
USA

Michelle L. Zaharik, PhD
Augurex Life Sciences Corp
Canada

Staff

Clinical and Laboratory Standards Institute
USA

Luann Ochs, MS
Project Manager

Megan L. Tertel, MA, ELS
Editorial Manager

Catherine E.M. Jenkins
Editor

Kristy L. Leirer, MS
Editor

Laura Martin
Editor

Acknowledgment for the Expert Panel on Evaluation Protocols

CLSI, the Consensus Council, and the Document Development Committee on Interference Testing in Clinical Chemistry gratefully acknowledge the Expert Panel on Evaluation Protocols for serving as technical advisors and subject matter experts during the development of this guideline.

Expert Panel on Evaluation Protocols

James H. Nichols, PhD, DABCC, FACB
Chairholder
Vanderbilt University School of Medicine
USA

Nils B. Person, PhD, FACB
Vice-Chairholder
Siemens Healthcare Diagnostics, Inc.
USA

Valeria L. Alcon, PhD
Health Canada
Canada

Jeffrey R. Budd, PhD
Beckman Coulter
USA

Mark D. Kellogg, PhD, MT(ASCP), DABCC, FAACC
Boston Children's Hospital
USA

Marina V. Kondratovich, PhD
FDA Center for Devices and Radiological Health
USA

Paula Ladwig, MS, MT(ASCP)
Mayo Clinic
USA

Robert J. McEnroe, PhD
USA

Curtis A. Parvin, PhD
Bio-Rad Laboratories, Inc.
USA

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Interference Testing in Clinical Chemistry gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Goce Dimeski, PhD, FFSc (RCPA)
Princess Alexandra Hospital
Australia

A. Paul Durham, MA
APD Consulting
USA

Beimar Iriarte, MS
Abbott
USA

James J. Miller, PhD, DABCC, FACB
University of Louisville Hospital
USA

W. Gregory Miller, PhD
Virginia Commonwealth University Health System
USA

Merle B. Smith, MBA, MS, MT(ASCP)
Siemens Healthcare Diagnostics, Inc.
USA

Oswald Sonntag, PhD
Bio-Rad Laboratories GmbH
Germany

Karen L. Warren, MS
Ortho-Clinical Diagnostics, Inc.
USA

Contents

Contents (Continued)

Foreword

Interferents can be a significant source of error in medical laboratory measurements.[2-4] Such errors can represent a hazard to the patient. Although performance is routinely monitored by internal QC and external quality assessment procedures, and accuracy can, in some cases, be verified by comparison to reference measurements, procedures, or materials (eg, commercial standards or weighed-in concentrations), laboratories cannot easily detect error caused by interferents. Therefore, manufacturers of *in vitro* diagnostic measuring systems need to include evaluation of potential interferents' effects in their risk analyses at the product design stage.

Although continually improving the selectivity of measurement procedures is a desirable goal, compromise is sometimes necessary to meet medical laboratories' needs. This guideline assists manufacturers and laboratories with evaluating interferents, determining the extent of interfering effects in the context of medical needs, and informing customers of known sources of medically significant error, in order to avert such errors. This guideline identifies many potential interferents to be evaluated in the risk management process.[5]

Manufacturers and medical laboratories are responsible for ensuring that measurement procedures are specific enough to meet the medical caregivers' needs. Laboratories should also investigate discrepant results for possible interferents and provide objective feedback to the manufacturers who supply their measuring systems.

To accommodate the variety of existing and future measurement procedures, this guideline is intended to provide recommendations instead of rigid protocols. The document development committee strived to achieve a balance between consistency of structured protocols and flexibility to accommodate the technology being evaluated. Laboratory scientists and manufacturers need to understand the scientific concepts, make informed choices, and work together toward the common goal of safeguarding patient care. Identifying an interference effect, evaluating its medical significance, determining its underlying cause, and ultimately improving the measurement procedure necessitates close cooperation between the laboratory and the manufacturer.

Background information is included to explain key chemical and statistical concepts.[6] It is important to note that this guideline focuses on interference with the examination portion of the measurement procedure. It does not include information on physiological effects caused by drugs and their metabolites. A series of recommendations on drug effects has been previously published as a compendium.[7,8] Comprehensive literature surveys of the analytical and physiological effects of drugs and other substances have also been published.[3,4,9,10]

Overview of Changes

This guideline replaces the previous edition of the approved guideline, EP07-A2, published in 2005. Several changes were made in this edition, including:

- Improved the process for conducting drug screening and characterization to make it simpler and easily performed
- Reviewed and updated the statistics used in determining interference
- Updated the appendixes, including clarifying their purpose and function
- Moved former Appendixes C (Interferent Test Concentrations) and D (Interference Test Concentrations for Endogenous Analytes) to the new supplement, CLSI document EP37,[1] so they may be updated more frequently

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

Evaluation
Interference
Interferent
Matrix effect
Risk management
Selectivity
Validation
Verification

Chapter 1

Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

Interference Testing in Clinical Chemistry

1 Introduction

1.1 Scope

This guideline is intended for manufacturers and medical laboratories, for two purposes:

- Assist manufacturers and other developers of laboratory measurement procedures in characterizing the effects of potential interferents on measurement procedures results by providing information on:
  - Relevant interferents and concentrations to be tested
  - Likely effects of the interferent on the concentration of the measurand of interest (ie, no effect, positive effect, or negative effect)
  - Scientifically valid experimental designs
  - Appropriate data analysis and interpretation
  - Stating meaningful interference claims
- Assist medical laboratories in investigating discrepant results that may be due to interferents by:
  - Defining a systematic investigation strategy
  - Specifying data collection and analysis procedures
  - Promoting greater cooperation between laboratory scientists and manufacturers so that new interferents are identified, disclosed, and ultimately eliminated

Any measurement procedure, quantitative or qualitative, may be subject to interference. This guideline is written for a broad spectrum of measurement procedures and measuring systems, with primary focus on quantitative methods and qualitative methods with interpretation based on numeric values. Modification may be necessary to accommodate the particular characteristics of the procedure being evaluated. Measurement procedures that use serum, plasma, whole blood, cerebrospinal fluid, urine, and most other body fluids can be evaluated for interferents using this guideline.

EP07 and its supplement, CLSI document EP37,[1] are not meant to include a complete list of interferents to be tested and do not stipulate that all potential interferents included in CLSI document EP37[1] are to be tested. However, EP07 and CLSI document EP37[1] are intended to provide a solid starting point for assessing interference effects. This guideline is limited to testing potential interference from chemical substances that may be exogenous (eg, drugs) or endogenous changes in concentrations of substances caused by disease processes (eg, bilirubin, lipoproteins).